University of Groningen

Identification and modulation of drug targets for precision medicine in breast, lung and ovarian cancer subtypes

Stutvoet, Thijs

DOI:
[10.33612/diss.144705120](https://doi.org/10.33612/diss.144705120)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Stutvoet, T. (2020). *Identification and modulation of drug targets for precision medicine in breast, lung and ovarian cancer subtypes*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.144705120>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Identification and modulation of drug targets for precision medicine in breast, lung and ovarian cancer subtypes

Thijs Simon Stutvoet

Cover illustration: Frederiek Jansen
Cover layout: Ilse Modder | www.ilsemodder.nl
Lay-out: Ilse Modder | www.ilsemodder.nl
Printed by: Gildeprint Enschede | www.gildeprint.nl

The work presented in this thesis was financially supported by the Junior Scientific Masterclass from the University of Groningen, the Stichting De Cock-Hadders, and the Van der Meer-Boerema Stichting.

Printing of this thesis was financially supported by the Graduate School of Medical Sciences, Stichting Werkgroep Interne Oncologie, and the University of Groningen

© 2020 T.S. Stutvoet

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior permission of the author or, when appropriate, the publisher of the published article.

rijksuniversiteit
 groningen

Identification and modulation of drug targets for precision medicine in breast, lung and ovarian cancer subtypes

Proefschrift

ter verkrijging van de graad van doctor
aan de Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

dinsdag 1 december 2020 om 11.00 uur

door

Thijs Simon Stutvoet

geboren op 25 december 1992
te Eindhoven

Promotores

Prof. dr. S. de Jong

Prof. dr. E.G.E. de Vries

Copromotor

Dr. R.S.N. Fehrmann

Beoordelingscomissie

Prof. dr. H.J. Guchelaar

Prof. dr. P.H. Elsinga

Prof. dr. H.W. Nijman

Table of contents

Chapter 1	General introduction & outline of the thesis	9
Chapter 2	Immunotherapeutic options on the horizon in breast cancer treatment <i>Pharmacology & Therapeutics, 2015</i>	17
Chapter 3	MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells <i>Journal of Pathology, 2019</i>	49
Chapter 4	Molecular imaging of PD-L1 expression and dynamics with a ¹⁸ F-labeled adnectin PET tracer <i>Journal of Nuclear Medicine, 2020, in press</i>	87
Chapter 5	A neuronal development-related transcriptomic footprint is associated with survival of patients with serous ovarian cancer <i>Manuscript in preparation</i>	109
Chapter 6	ATR inhibition sensitizes ovarian clear cell cancer cells to cisplatin <i>Manuscript in preparation</i>	155
Chapter 7	Summary and future perspectives	173
Chapter 8	Nederlandse samenvatting	187
Appendices	Dankwoord	193